OBJECTIVES: To use a discrete choice experiment (DCE) to evaluate preferences for the actual treatment features and overall profiles of two injectable glucagon-like peptide-1 (GLP-1) receptor agonists (dulaglutide and liraglutide) among patients with type 2 diabetes (T2DM) in the United Kingdom (UK). METHODS: In-person interviews were conducted in the UK to administer a DCE to patients with self-reported T2DM, naïve to treatment with injectable medications. The DCE examined 6 attributes of T2DM treatment each described by 2 levels: ‘dosing frequency,’ ‘HbA1c change,’ ‘weight change,’ ‘type of delivery system,’ ‘frequency of nausea,’ and ‘frequency of hypoglycemia.’ Part-worth utilities were estimated using random effects logit models and used to calculate relative importance values for each attribute. A Chi-square test was used to determine differences in preferences for dulaglutide vs. liraglutide profiles. RESULTS: A total of 243 participants [mean age: 60.5 (SD 10.9) years; 76.1% male; mean BMI: 29.8 (SD 5.4) kg/m] completed the study. Relative importance values for the attributes in rank order were: ‘dosing frequency’ (41.6%), ‘type of delivery system’ (35.5%), ‘frequency of nausea’ (10.4%), ‘weight change’ (5.9%), ‘HbA1c change’ (3.6%), and ‘frequency of hypoglycemia’ (3.0%). Significantly more participants preferred the dulaglutide profile (83.1%) compared to the liraglutide profile (16.9%; p<0.0001). CONCLUSIONS: This study elicited patients’ preferences for attributes and levels representing the actual characteristics of two specific GLP-1 medications. In this context, dosing frequency and type of delivery system were most important, accounting for over 75% of the relative importance. While previous studies have identified efficacy as highly important in T2DM medication decisions, this study suggests that when differences in efficacy between medications are small, other treatment features (e.g., dosing frequency and delivery system) are of much greater importance to patients.